Matteo S. Carlino
0000-0002-7861-4104
Melanoma Institute Australia
265 papers found
Refreshing results…
Rechallenge with combination ipilimumab and anti-PD-1 (IPI+ PD1) in metastatic melanoma after acquired resistance to IPI+ PD1 immunotherapy
Epacadostat Plus Pembrolizumab versus Placebo Plus Pembrolizumab in Patients with Unresectable or Metastatic Melanoma: Results of the Phase 3, Randomised, Double-Blind Echo-301/Keynote-252 Study
Intratumoral IL-12 plus pembrolizumab combination therapy in treatment refractory solid tumors: a safety and biomarker analysis
Liver toxicity in patients with non-small-cell lung cancer treated with nivolumab-pembrolizumab: A retrospective study
Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study
original reports abstract Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+ PD1).
Targeted melanoma therapies as radiosensitizers
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (vol 25, pg 936, 2019)
Genomic landscape of patient-matched tumor and circulating cell-free DNA in metastatic melanoma
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
Management of melanoma recurrence following adjuvant anti-PD1 therapy
Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis
Pre-treatment circulating cytokines predict toxicity with combination anti-PD1 and anti-CTLA4 immunotherapy
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
Immune Checkpoint Inhibitor Toxicity
Abstract CT001: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma:
PO-513 Using mapk and pi3k signalling to predict patient outcome in resectable stage iiib/c melanoma patients neoadjuvantly treated with dafrafenib and trameitinib
Missing publications? Search for publications with a matching author name.